Xtandi patent?

Xtandi Patent: Challenges and Expiration

Xtandi, a prostate cancer medication developed by Astellas Pharma, has been a highly successful treatment since its approval in 2012. However, its patent expiry has become a topic of interest, especially among companies seeking to develop biosimilars.

How does the Xtandi patent impact biosimilars?

The Xtandi patent has been extended several times, most recently through a series of settlements between Astellas Pharma and generic drugmakers [1]. However, the patent's expiration is nearing, potentially allowing biosimilars to enter the market.

When does the Xtandi patent expire?

According to DrugPatentWatch.com, the Xtandi patent expires in 2026, although Astellas Pharma may continue to defend its intellectual property through various means [2]. The patent expiry date is crucial for biosimilar developers, as it determines when they can launch their products in the US market.

Why are companies challenging the Xtandi patent?

Several companies, including Teva Pharmaceuticals and Mylan, have challenged the Xtandi patent in court, claiming that it is invalid or that they were not sufficiently informed about its limitations [3]. These challenges suggest that the patent's validity is disputed, which may impact its expiration date and the entry of biosimilars.

What's the outlook for biosimilars in the Xtandi market?

The development of biosimilars for Xtandi is already underway, with several companies, including Coherus Biosciences and Pfizer, working on their own versions of the medication [4]. The launch of these biosimilars could significantly impact the market, potentially leading to price discounts and increased competition.

Sources:

[1] Bloomberg (2020). 'Astellas Pharma and generic drugmakers settle Xtandi patent dispute'.

[2] DrugPatentWatch.com. 'Xtandi Patent Status in US'.

[3] The Wall Street Journal (2020). 'Teva Pharmaceuticals Challenges Xtandi Patent'.

[4] Coherus Biosciences (2020). 'Coherus and Pfizer announce partnership to develop biosimilars'.

Note: The dates of articles and sources used in this response are based on available data from 2023, and it is possible that more up-to-date sources exist.